

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/698,228 10/30/2003		Yusuke Nakamura	56801 DIV (46342)	7445		
21874	7590 11/15/2005			EXAMINER		
EDWARD	S & ANC	GELL, LLP	SWOPE, SHERIDAN			
P.O. BOX 5			ART UNIT	PAPER NUMBER		
BOSTON,	MA 0220	05		FAI ER NOMBER		
			1656			

DATE MAILED: 11/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application	n No.	Applicant(s)					
Office Action Summary			10/698,22		NAKAMURA ET AL.					
			Examiner		Art Unit					
			Sheridan L	Swope	1656					
۔۔ Period for F	The MAILING DATE of this commun Reply	ication appe	ears on the	cover sheet with the c	correspondence a	ddress				
WHICHE - Extension after SIX - If NO per - Failure to Any reply	RTENED STATUTORY PERIOD F EVER IS LONGER, FROM THE M ns of time may be available under the provisions (6) MONTHS from the mailing date of this comn iod for reply is specified above, the maximum st or reply within the set or extended period for reply or received by the Office later than three months a atent term adjustment. See 37 CFR 1.704(b).	MAILING DA s of 37 CFR 1.13 nunication. atutory period wi will, by statute,	ATE OF TH 66(a). In no eve ill apply and wil cause the appli	IS COMMUNICATION Int, however, may a reply be tire I expire SIX (6) MONTHS from cation to become ABANDONE	N. nely filed the mailing date of this o D (35 U.S.C. § 133).	•				
Status			•							
1)⊠ Re	esponsive to communication(s) file	ed on 30 Oc	rtober 2003	·						
·										
	, <del>-</del>									
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Disposition	·			.,,						
	•	application	,	•						
	Claim(s) <u>19-26</u> is/are pending in the application.									
	4a) Of the above claim(s) is/are withdrawn from consideration.									
,	· / ——									
,										
	aim(s) <u>22</u> is/are objected to: aim(s) are subject to restric	tion and/or	election re	auiromont	•					
0) <u> </u>	airi(s) are subject to restric	Juon and/or	election re	quirement.						
Application	Papers				•					
9)⊠ Th	e specification is objected to by th	e Examiner	•							
10)⊠ Th	e drawing(s) filed on <u>30 October 2</u>	2003 is/are:	a)⊠ acce	pted or b) objected	to by the Examir	ner.				
Ар	plicant may not request that any object	ction to the d	frawing(s) be	e held in abeyance. See	e 37 CFR 1.85(a).					
						FR 1.121(d).				
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority und	ler 35 U.S.C. § 119				•					
	12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:									
1.[	1. Certified copies of the priority documents have been received.									
2.[	<ul> <li>2.  Certified copies of the priority documents have been received in Application No. 10/019,733.</li> </ul>									
_	3. Copies of the certified copies of the priority documents have been received in this National Stage									
	application from the International Bureau (PCT Rule 17.2(a)).									
* See the attached detailed Office action for a list of the certified copies not received.										
			•			•				
Attachment(s)										
` ` `	References Cited (PTO-892)			4) Interview Summary	(PTO-413)					
2) 🔲 Notice of	Draftsperson's Patent Drawing Review (P			Paper No(s)/Mail Da	ite					
	on Disclosure Statement(s) (PTO-1449 or	atent Application (PT0	O-152)							
Paper No(s)/Mail Date <u>1003;0604</u> . 6)										

Application/Control Number: 10/698,228

Art Unit: 1656

#### **DETAILED ACTION**

Pending Claims 19-26, which encompass a single invention directed to a nucleic acid molecule encoding a ribonucleotide reductase polypeptide, vector, host cells, and methods of making the encoded protein, class 435, subclass 189, are hereby examined.

### **Priority**

The priority date of the instant invention is taken to be June 28, 1999, the filing date of JP 18113/1999, which discloses the polypeptide of SEQ ID NO: 1 and the polynucleotides of SEQ ID NO: 2 and SEQ ID NO: 12.

### Specification-Objections

The specification is objected to for the following reasons.

The claim to priority in the first paragraph should be updated to reflect the status of parent applications.

Pages 5-9 encompass a large blank space have a few non-understandable characters.

#### Title

The title is objected to for not being descriptive of the instant invention.

#### Claims-Objections

The claim set is objected to for not beginning with a sentence of which the claims are an object e.g., "We claim" or "The claims are".

## Claim Rejections - 35 USC § 112-Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1656

Claims 24 and 25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The word "transformant" in Claim 24 renders Claims 24 and 25 indefinite because "transformant" can be used to describe both transformed cells and transformed organisms. Neither the specification nor the claims specifically define "transformant"; therefore, a person of ordinary skill in the art would not know the metes and bounds of the recited invention. For purposes of examination, since the specification uses the term "transformant" when describing host cells (for example on pg 27), but "DNA-transferred" when describing organisms (for example pgs 57-65), it is assumed that "transformant" refers to transformed cells.

### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 19-21 and 23-26 are rejected under 35 U.S.C. 102(e) as being anticipated by Tang et al, 2000 (IDS; priority date 17-SEP-1998). Tang et al teach the polynucleotide of SEQ ID NO: 2, which encodes the polypeptide of SEQ ID NO: 1 (see enclosed alignments). Tang et al further teach their polynucleotide in a vector, in a host cell, and used for making the encoded protein. Therefore, Claims 19-21 and 23-26 are rejected under 35 U.S.C. 102(e) as being anticipated by Tang et al, 2000.

Application/Control Number: 10/698,228

Art Unit: 1656

Allowable Subject Matter

Claim 22 is objected to as being dependent upon a rejected base claim, but would be

allowable if rewritten in independent form including all of the limitations of the base claim and

any intervening claims.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sheridan L. Swope whose telephone number is 571-272-0943.

The examiner can normally be reached on M-F; 9:30-7 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Kathleen Kerr can be reached on 571-272-0931. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published application

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on the access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sheridan Lee Swope, Ph.D.

Art Unit 1656

SHERIDAN SWOPE, Ph.D.

Page 4